Abvc Biopharma (ABVC) Interest Expenses (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Interest Expenses came in at $2.2 million in Q1 2026, down 66.97% YoY from $6.6 million in Q1 2025, and up 535.81% on a QoQ basis from $342035.0 in Q4 2025.
Abvc Biopharma (ABVC) Interest Expenses (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 17 years of Interest Expenses data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Interest Expenses fell 66.97% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 66.97% YoY) and the FY2025 annual result came in at $415890.0, down 49.64% from the prior year.
- Interest Expenses advanced to $2.2 million in Q1 2026, from $342035.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $7.6 million in Q1 2023 to a low of -$1.4 million in Q4 2023.
- A 5-year average of $2.9 million and a median of $803926.0 in 2024 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 42899.28% in 2023, down 1109.11% in 2023.
- Tracing ABVC's Interest Expenses over 5 years: stood at $134461.0 in 2022, then plunged by 1109.11% to -$1.4 million in 2023, then jumped by 159.25% to $803926.0 in 2024, then slumped by 57.45% to $342035.0 in 2025, then jumped by 535.81% to $2.2 million in 2026.
- The last three Interest Expenses figures came in at $2.2 million (Q1 2026), $342035.0 (Q4 2025), and $275000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 42,323.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.70 Mn |
| Jun 30, 2026 | 7.70 Mn |
| Mar 31, 2026 | 2.17 Mn |
| Mar 31, 2026 | 2.17 Mn |
| Dec 31, 2025 | 342,035.00 |
| Dec 31, 2025 | 342,035.00 |
| Sep 30, 2025 | 275,000.00 |
| Sep 30, 2025 | 275,000.00 |
| Jun 30, 2025 | 6.76 Mn |
| Jun 30, 2025 | 6.76 Mn |
| Mar 31, 2025 | 6.58 Mn |
| Mar 31, 2025 | 6.58 Mn |
| Dec 31, 2024 | 803,926.00 |
| Dec 31, 2024 | 803,926.00 |
| Sep 30, 2024 | 648,716.00 |
| Sep 30, 2024 | 648,716.00 |
| Jun 30, 2024 | 6.24 Mn |
| Jun 30, 2024 | 6.24 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Mar 31, 2024 | 6.25 Mn |